BBHC
ALNY icon

Brown Brothers Harriman & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.9K Buy
76
+21
+38% +$6.33K ﹤0.01% 1267
2026
Q1 		$18.2K Sell
55
-125
-69% -$42.5K ﹤0.01% 1243
2025
Q4 		$71.6K Buy
180
+7
+4% +$3.1K ﹤0.01% 974
2025
Q3 		$78.9K Buy
173
+19
+12% +$7.74K ﹤0.01% 918
2025
Q2 		$50.2K Buy
154
+127
+470% +$35.1K ﹤0.01% 938
2025
Q1 		$7.29K Sell
27
-3
-10% -$771 ﹤0.01% 1108
2024
Q4 		$7.06K Sell
30
-22
-42% -$5.79K ﹤0.01% 1179
2024
Q3 		$14.3K Buy
52
+25
+93% +$6.51K ﹤0.01% 992
2024
Q2 		$6.56K Hold
27
– – ﹤0.01% 1008
2024
Q1 		$4.04K Sell
27
-375
-93% -$62.6K ﹤0.01% 1054
2023
Q4 		$76.9K Sell
402
-240
-37% -$40.9K ﹤0.01% 662
2023
Q3 		$114K Buy
642
+615
+2,278% +$117K ﹤0.01% 573
2023
Q2 		$5.13K Hold
27
– – ﹤0.01% 1049
2023
Q1 		$5.41K Buy
+27
New +$5.67K ﹤0.01% 1055
2019
Q4 		– Sell
-123
Closed -$10K – 1110
2019
Q3 		$10K Hold
123
– – ﹤0.01% 884
2019
Q2 		$9K Buy
123
+3
+3% +$230 ﹤0.01% 827
2019
Q1 		$11K Buy
+120
New +$10K ﹤0.01% 821
2018
Q2 		– Sell
-15
Closed -$2K – 810
2018
Q1 		$2K Sell
15
-20
-57% -$2.58K ﹤0.01% 742
2017
Q4 		$4K Buy
+35
New +$4.4K ﹤0.01% 872
2015
Q2 		– Sell
-40
Closed -$4K – 744
2015
Q1 		$4K Hold
40
– – ﹤0.01% 704
2014
Q4 		$4K Buy
+40
New +$3.71K ﹤0.01% 763

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brown Brothers Harriman & Co's ALNY Position: Q2 2026 in Review

Brown Brothers Harriman & Co increased its Alnylam Pharmaceuticals (ALNY) stake by 38% in Q2 2026, buying an estimated $6.33K and bringing the position to 76 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

Brown Brothers Harriman & Co first reported a position in ALNY in Q4 2014 and has held it in 21 quarters since. The position peaked at $114K in Q3 2023. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Brown Brothers Harriman & Co held 76 shares of Alnylam Pharmaceuticals worth $22.9K as of Q2 2026.
  • Brown Brothers Harriman & Co bought 21 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.33K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1267 holding.
  • Brown Brothers Harriman & Co first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 21 quarters since.
  • Brown Brothers Harriman & Co's Alnylam Pharmaceuticals position peaked at $114K in Q3 2023.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.